Prognostic factors for progression‑free survival and overall survival in patients with advanced gastric cancer treated with fluoropyrimidine‑based first‑line chemotherapy
More details
Hide details
Klinika Onkologii CSK MON WIM w Warszawie; kierownik: prof. dr hab. n. med. Cezary Szczylik
Submission date: 2016-09-19
Publication date: 2016-12-05
LW 2017;95(1):68–75
Introduction. A fluoropyrimidine‑based chemotherapy (FBC) remains the standard first‑line palliative treatment for patients with advanced gastric cancer (AGC). The aim of the study. Identification of features that may influence on progression‑free survival (PFS) and overall survival (OS) in this group of patients. Material and methods. This retrospective study included consecutive patients with AGC who had begun treatment with a first‑line FBC during the period 2010–2015 at the Department of Oncology, Military Institute of Medicine (Warsaw, Poland). The Kaplan‑Meier method was used to estimate medians for PFS and OS. Multivariate Cox proportional hazards regression was used to identify factors independently associated with PFS and OS. Results. 129 patients were included for analysis. The median PFS and OS were 4.3 and 8.0 months, respectively. Eastern Cooperative Oncology Group performance status (ECOGPS) (Hazard Ratio [HR]: 2.198, p = 0.029), peritoneal metastases (PM) (HR: 1.920, p = 0.025) and lung metastases (LM) (HR: 2.259, p = 0.046) were prognostic factors for PFS. ECOGPS (HR: 2.419, p = 0.017), PM (HR: 1.776, p = 0.037), LM (HR: 2.864, p = 0.007) and serum albumin (SA) (HR: 0.524, p = 0.047) were prognostic factors for OS. Conclusions. ECOGPS, PM and LM were independently associated with PFS, whereas ECOGPS, PM, LM and SA with OS.
No conflicts of interest were declared.